Dr. Tianyuan Wang, currently the CEO of Clickmab Bio and formerly the head of the biopharmaceutical business at XtalPi, holds a bachelor's degree from the University of Science and Technology of China. During his doctoral studies at the Institute of Biophysics of the Chinese Academy of Sciences, he conducted research on protein engineering and design. At Clickmab Bio, Dr. Wang led the team in independently developing a generative AI-based de novo antibody design algorithm and a large language model-driven multi-agent antibody design platform, Click.mAb. This marked the first global proof-of-concept for wet-wet hybrid de novo antibody design targeting specific epitopes, with algorithm accuracy comparable to that of the 2024 Nobel laureate David Baker's team. Dr. Wang possesses extensive experience in AI+biomacromolecule algorithm development, practical implementation of AI in biopharmaceutical R&D, cross-disciplinary team management and collaboration, as well as project incubation and industry-academia-translation driven by cutting-edge technologies.